Health Wildcatters Names 14th Startup Cohort Ahead of INVEST Digital Health

Health Wildcatters, the Dallas-based accelerator and MedCity News partner, has unveiled its 14th cohort of healthcare startups. Ten companies made the cut this year, drawn from the U.S., Canada, and Israel. A third are female-founded or female-led, according to an emailed press release. The announcement precedes INVEST Digital Health, set for October 29 at Pegasus Park, the same campus that houses the accelerator.

The timing is not incidental. Pegasus Park has positioned itself as a startup and healthcare innovation hub, and pairing a cohort reveal with a major investment conference gives these companies immediate visibility with capital allocators. For early-stage healthcare ventures, that kind of exposure matters more than most press coverage.

The cohort spans a wide swath of the digital health and biotech landscape. Atomistic Insights, co-founded by Katie Kuo and Shiyao Bao, applies physics-guided AI to protein dynamics through its DeepPath platform, aiming to reveal drug-binding pockets that traditional discovery methods miss. Calaris Diagnostics, founded by Dr. Jim Chen, is building saliva-based diagnostics for early detection of fatty liver disease, starting with MASLD and MASH. Venom Biologics, led by CEO and co-founder Neil Luhar, is developing non-opioid pain treatments, including a peptide derived from scorpion venom that targets the NaV1.8 sodium channel in pain-sensing neurons.

Operational and workforce challenges get equal billing. DISCHARGEpath, founded by Sean Elwell, automates hospital discharge coordination, covering eligibility checks, prior authorization, post-acute placement, durable medical equipment, transportation, and remote monitoring in a single agentic AI platform. EquiShift, led by CEO Snehita Sana, forecasts patient demand and generates shift-specific staffing recommendations for hospitals trying to control labor costs and reduce clinician burnout. Full Time Nurse Staffing Inc., founded by Brett McDonald, takes a more direct approach to the nursing shortage: recruiting, training, licensing, and employing registered nurses from Mexico.

Three more companies round out the group. MG Health Tech, led by founder and CEO Ganesh Natesan, combines AI, connected-device engineering, and proprietary sensor hardware for real-time care delivery. PatientX, co-founded by Farah Ahmad and Jodie Huddleston, benchmarks patient experience in clinical trials, using AI analytics to help pharmaceutical sponsors identify retention barriers. SanaOculis, led by CEO Soumendu Bhattacharya, is developing a non-invasive neurostimulation device intended to halt progression of vision-affecting glaucoma. Sub-Q Bionics, under CEO Jordan Pollack, is building a fully implantable bionic lymphatic drainage system for lymphedema, a condition that disproportionately affects cancer survivors who have had lymph nodes removed.

Convenience as Clinical Strategy

The cohort announcement lands alongside a conference panel that speaks directly to where digital health investment is heading. Health Wildcatters co-founder and CEO Dr. Hubert Zajicek will moderate a discussion on how convenience is reshaping clinical strategy, a theme that cuts across nearly every company in this cohort.

The panel's premise is straightforward. Patients now expect the same frictionless experience from healthcare that they get from retail, banking, or food delivery. Providers who fail to deliver that convenience risk losing patients to competitors who do, and the panel will explore how meeting those expectations can improve loyalty, adherence, and outcomes. Panelists include Angeline Chen, founding director of product at Novellia, Arpan Parikh, CEO of Kin Health, and Travis Rush, CEO of Reperio Health.

This is not an abstract concern for a conference stage. It is the operating thesis behind several of the cohort companies. DISCHARGEpath's automated discharge coordination exists because manual handoffs between hospitals, payers, and post-acute providers create delay and friction at exactly the moment patients are most vulnerable. EquiShift's staffing forecasts exist because chronic understaffing degrades the patient experience before a single clinical decision gets made. Convenience, in this framing, is not a nice-to-have feature. It is infrastructure.

Zajicek framed the cohort's potential in similarly ambitious terms. "We are thrilled to welcome 10 innovative healthcare startups to Dallas and the rapidly growing North Texas healthcare ecosystem," he said. "In the years ahead, the innovation driven by these 10 startups has the potential to address some of healthcare's most complex challenges and shape the future of care."

That is standard accelerator rhetoric, and investors should treat it as such. Ten companies at this stage will not uniformly succeed. Diagnostics and drug discovery ventures like Calaris and Atomistic Insights face long regulatory and validation timelines before any revenue materializes. Workforce and operations plays like EquiShift and Full Time Nurse Staffing face shorter paths to traction but smaller total addressable markets. Device companies like SanaOculis and Sub-Q Bionics sit somewhere in between, dependent on clinical trial outcomes and reimbursement pathways that can take years to resolve.

The Bottom Line

North Texas continues building out its case as a secondary healthcare innovation hub, and Health Wildcatters' 14th cohort adds another data point to that narrative. The geographic and founder diversity here, spanning three countries with a third of companies female-founded, suggests the accelerator is casting a wide net rather than optimizing for a narrow thesis.

For investors tracking digital health, the more useful signal may be the convenience panel rather than the cohort itself. Startups pitching operational efficiency, patient experience, and workforce automation are chasing a real and immediate pain point in healthcare delivery, not a speculative future state. Diagnostics and therapeutics ventures carry higher risk and longer horizons but larger potential payoffs if they clear regulatory hurdles. Anyone evaluating this cohort should weight exposure accordingly: near-term operational plays for steadier, if smaller, returns, and biotech or device plays for asymmetric upside contingent on clinical and regulatory execution. The full conference agenda and registration details are available through the INVEST Digital Health event page.